Neuren Pharma (ASX:NEU) has seen its shares jump over +11% as the company wins a patent to treat Pitt Hopkins Syndrome (PTHS) with its drug NNZ-2591.
Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more.
During clinical trials treating PTHS with the drug over 13 weeks, Neuren reported that neuropsychological “improvements were seen.”
PTHS is typically marked by pronounced intellectual disability and can also produce breathing problems among myriad afflictions. While the syndrome itself is not life-threatening, its complications can be.
“There are currently no approved treatments for PTHS, which has a severely debilitating impact on the lives of patients, as well as their parents and siblings,” Neuren wrote on Thursday.
It fits the company’s overall profile. It already focuses on drugs treating rare conditions in children, the best known being DAYBUE.
In February of 2024, DAYBUE became the subject of a short seller report which briefly tanked the NEU share price.
But the stock shook that off relatively shortly after.
More market news
Meet GeoGeorge: The HotCopper poster so accurate he got hired as an analyst
Expanding again: Paradigm adds new oral combo IP to OS drug stable
Still, 1Y returns for Neuren shareholders are down -33%, though that isn’t related to the short seller report.
Stocks appear to have begun a downward trajectory last August when the company’s Phase 2 results in a trial treating Angelman Syndrome failed to impress.
Neuren is also listed on the NASDAQ.
NEU last traded at $13.95/sh.
Jonathon Davidson
The Market Online, Australia
https://media.hotcopper.com.au/authors/V1-Jonathon.jpg
jonathon-davidson/988
https://media.hotcopper.com.au/embed/bd9jh3rs0fuyvdjtm6uhygrp6n/1/large
(20min delay)